The paper reviews the outcomes of clinical use of bioregulator Traumeel® S in patients with acute and subacute disorders of musculoskeletal system, including traumas and athletic injuries. The formulation of Traumeel® contains 12 plant ingredients and 2 mineral ingredients at low concentrations. It provides analgesic, anti-edema, and anti-exudative action. Traumeel® rapidly reduces inflammation and pain, resolves hemorrhages, and promotes recovery. The data on the clinical use of Traumeel® are summarized. While being not inferior to NSAIDs, this drug is better tolerated by the patients and can be considered as an alternative to conventional NSAIDs.
The search was performed in AMED, PubMed, Embase, and Cochrane Library databases for articles on Traumeel® use. The author analyzed all clinical studies of Traumeel® and/or its components beginning from 1966. These studies included data on treatment efficacy, side effects (clinical and laboratory parameters were evaluated), and mechanisms of action of this agent.
The data on the efficacy and safety of Traumeel® S, its components, placebo, and active control are reviewed in the context of current immunological terminology.

Keywords: Traumeel S, sports injury, hemarthrosis, epicondylitis, tendinitis, chemotherapy, immunomodulation, bioregulatory drug

For citation: Mar'yanovskiy A.A. Treatment of rheumatologic diseases in the context of bioregulation: analytical survey // RMJ. Rheumatology. 2016. № 2. P. –115.